Conference Paper: An investigation on p21-activated protein kinase 1 inhibitor, IPA-3, in hepatocellular carcinoma
| Title | An investigation on p21-activated protein kinase 1 inhibitor, IPA-3, in hepatocellular carcinoma |
|---|---|
| Authors | Wong, LLY Lam, IPY Wong, TYN Lai, WL Zhou, Y Hung, WY Ching, YP |
| Issue Date | 2012 |
| Publisher | American Association for Cancer Research. |
| Citation | The 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012. [How to Cite?] |
| Abstract | BACKGROUND: Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to metastasis and tumor recurrence. However, apart from Sorafenib, there is no proven effective systemic chemotherapy for HCC yet. Our previous study showed that overexpression of p21-activated protein kinase 1 (PAK1) is commonly found in HCC, which is coupled with a more aggressive tumor behavior. In this study, we examined the effect of an allosteric inhibitor of PAK1, IPA-3, on hepatocarcinogenesis. METHODS: Human HCC line H2M was treated with various dosages of IPA-3 or ... |
| Description | Poster Session 20 - Pathogenesis of Gastrointestinal and Hepatocellular Carcinomas: abstract no. 4429 |
| dc.contributor.author | Wong, LLY |
|---|---|
| dc.contributor.author | Lam, IPY |
| dc.contributor.author | Wong, TYN |
| dc.contributor.author | Lai, WL |
| dc.contributor.author | Zhou, Y |
| dc.contributor.author | Hung, WY |
| dc.contributor.author | Ching, YP |
| dc.date.accessioned | 2012-06-22T06:29:49Z |
| dc.date.available | 2012-06-22T06:29:49Z |
| dc.date.issued | 2012 |
| dc.description.abstract | BACKGROUND: Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to metastasis and tumor recurrence. However, apart from Sorafenib, there is no proven effective systemic chemotherapy for HCC yet. Our previous study showed that overexpression of p21-activated protein kinase 1 (PAK1) is commonly found in HCC, which is coupled with a more aggressive tumor behavior. In this study, we examined the effect of an allosteric inhibitor of PAK1, IPA-3, on hepatocarcinogenesis. METHODS: Human HCC line H2M was treated with various dosages of IPA-3 or ... |
| dc.description.nature | link_to_OA_fulltext |
| dc.description | Poster Session 20 - Pathogenesis of Gastrointestinal and Hepatocellular Carcinomas: abstract no. 4429 |
| dc.description.other | The 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012. |
| dc.identifier.citation | The 103rd Annual Meeting of the American Association for Cancer Research (AACR 2012), Chicago, IL., 31 March-4 April 2012. [How to Cite?] |
| dc.identifier.hkuros | 199949 |
| dc.identifier.uri | http://hdl.handle.net/10722/149198 |
| dc.language | eng |
| dc.publisher | American Association for Cancer Research. |
| dc.publisher.place | United States |
| dc.relation.ispartof | Annual Meeting of the American Association for Cancer Research |
| dc.title | An investigation on p21-activated protein kinase 1 inhibitor, IPA-3, in hepatocellular carcinoma |
| dc.type | Conference_Paper |